Further Insights (Qualitative Stream) into the management of T2DM
Research type
Research Study
Full title
Further Insights (Qualitative Stream) into the management of type 2 diabetes: Using qualitative research to enhance real-world evidence (RWE) data collected via electronic patient records (EPR)
IRAS ID
230092
Contact name
Simon de Lusignan
Contact email
Sponsor organisation
Eli Lilly and Company Ltd.
Duration of Study in the UK
1 years, 5 months, 15 days
Research summary
BACKGROUND:\n\nElectronic patient records (EPRs) were introduced in primary care to replace paper-based records and improve the quality, safety and efficiency of healthcare. In the UK, EPRs in primary care are coded using Read codes. These data have some limitations such as for diabetes, since people are often misdiagnosed, misclassified or miscoded. In addition, the EPR does not give the complete picture of patient and practitioner interaction, as much of the information discussed between a practitioner and patient (e.g. reasons for prescribing or not prescribing a treatment) is not recorded using existing coding systems. \n\nOBJECTIVES: \n\nTo describe, explore, and develop understanding of:\n\n1)\tPrimary care practitioner and patient attitudes toward adherence/persistence to medications, and injectable therapies; \n2)\tWhether healthcare disparities in the treatment of people with type 2 diabetes (T2DM) exist, and if so, why;\n3)\tComponents of the clinical consultation not recorded in computer medical records.\n\nMETHODOLOGY:\n\nWe will recruit up to eight practices from the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) network of sentinel GP practices to take part in qualitative research. These will be representative of each major computerised medical record (CMR) system supplier. \n\nWe will develop a qualitative research toolkit to capture data through a variety of research methods, which will be run in predetermined order: focus groups, simulated surgeries, and online surveys. Our sample will include patients with T2DM, and primary care practitioners. Framework analysis will be used.\n\nANTICIPATED OUTCOMES:\n\nThe study will supplement our previous research into adherence and persistence including disparities) to medications and use of injectable therapies of T2DM patients, by providing answers to questions that data recorded in electronic patient records can’t answer alone. We aim to provide additional insights into what is already known on the initiation of injectable therapies in primary care, medication adherence, and treatment disparities in T2DM. \n
REC name
London - Hampstead Research Ethics Committee
REC reference
17/LO/1305
Date of REC Opinion
2 Aug 2017
REC opinion
Favourable Opinion